HRTX Heron Therapeutics (HRTX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000818033
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
81
13F, latest reported quarter
Conversions, 180 days
17
Codes C/M, not in net · no price filed
Heron Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for HERON THERAPEUTICS, INC. /DE/ in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 8.2% of the 29,100,728 shares held after it.
- 1 other insider bought within 30 days.
- 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Rosen David Efraim bought about $3.6M of HRTX on Aug 8, 2025, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 81 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jul 21, 2023.
- The trade is 20.2% of the 8,753,290 shares held after it.
- 1 other insider bought within 30 days.
- 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Morgan Adam bought about $2.6M of HRTX on Aug 8, 2025, the largest insider purchase at the company since 2023; 1 other insider bought within 30 days and 81 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 16, 2023.
- The trade is 31.6% of the 79,000 shares held after it.
- 2 other insiders bought within 30 days.
- 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Development Officer Forbes William P bought about $27.3K of HRTX on Nov 17, 2023; 2 other insiders bought within 30 days and 81 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 92.6% of the 54,000 shares held after it.
- 2 other insiders bought within 30 days.
- 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Development Officer Forbes William P bought about $47.0K of HRTX on Nov 16, 2023; 2 other insiders bought within 30 days and 81 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 80.4% of the 186,496 shares held after it.
- 2 other insiders bought within 30 days.
- 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Collard Craig A bought about $138.0K of HRTX on Nov 16, 2023; 2 other insiders bought within 30 days and 81 funds added in the latest 13F quarter.12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
81 funds bought in last quarter
more than 60% of Pharma & Biotech
Revenue
+7.4% year over year
more than 56% of Pharma & Biotech
Margin
-13.0% net margin
more than 63% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
25.1% of the float short (float per yahoo 2026-10-27) · 14.2 days to cover · settled 2026-10-15
more than 93% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch HRTX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-74.8%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HRTX: institutional holders (13F)
13F holdings, latest reported quarter
30,046,828 sh
$12.8M
11,383,961 sh
$4.9M
10,550,750 sh
$4.5M
8,753,290 sh
$3.7M
7,782,741 sh
$3.3M
Congress trades in HRTX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
HRTX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
HRTX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Jacob Discovery Fund
$188.8K position · as of 2026-05-31
1.2%
Invesco NASDAQ Future Gen 200 ETF
$56.2K position · as of 2026-05-31
0.3%
SIIT SMALL CAP FUND
$35.5K position · as of 2026-05-31
0.0%
SIIT SMALL CAP II FUND
$39.6K position · as of 2026-05-31
0.0%
iShares Micro-Cap ETF
$229.3K position · as of 2026-06-30
0.0%
VANGUARD RUSSELL 2000 VALUE INDEX FUND
$90.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
24 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
12
Phase 2
0 active
6
Phase 3
0 active
4
Phase 4
0 active
1
Not applicable
0 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Craig Collard
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$3.4M
$3.5M
$1.5M
-93%
-9%
2022
$1.1M
-$2.8M
$1.4M
-88%
-11%
2021
$5.4M
-$1.0M
$1.6M
-57%
-1%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 81 funds added last quarter. Each figure is a federal filing, dated the day it went public.
HRTX financials
Revenue growth
+7.4%
XBRL, annual
Net margin
-13.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$151.2M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM HRTX
| FY Dec 2025 | $154.9M |
| FY Dec 2024 | $144.3M |
| FY Dec 2023 | $127.0M |
| FY Dec 2022 | $107.7M |
| FY Dec 2021 | $86.3M |
| Jun 2026 | $37.7M |
| Mar 2026 | $34.7M |
| Dec 2025 | $40.6M |
| Sep 2025 | $38.2M |
| Jun 2025 | $37.2M |
| Mar 2025 | $38.9M |
| Dec 2024 | $40.8M |
| Sep 2024 | $32.8M |
At each fiscal year end
Single quarter
Net margin, TTM
-22.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM HRTX
| FY Dec 2025 | -12.9% |
| FY Dec 2024 | -9.7% |
| FY Dec 2023 | -87.4% |
| FY Dec 2022 | -169.0% |
| FY Dec 2021 | -255.9% |
| Jun 2026 | -14.6% |
| Mar 2026 | -23.4% |
| Dec 2025 | -6.8% |
| Sep 2025 | -45.8% |
| Jun 2025 | -6.4% |
| Mar 2025 | +6.8% |
| Dec 2024 | +8.0% |
| Sep 2024 | -14.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$12.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM HRTX
| FY Dec 2025 | -$27.9M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -$60.3M |
| FY Dec 2022 | -$148.7M |
| FY Dec 2021 | -$206.4M |
| Jun 2026 | -$2.4M |
| Mar 2026 | -$1.9M |
| Dec 2025 | -$9.2M |
| Sep 2025 | $1.3M |
| Jun 2025 | -$11.1M |
| Mar 2025 | -$9.0M |
| Dec 2024 | -$12.4M |
| Sep 2024 | $2.9M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity HRTX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt HRTX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity HRTX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -399.4% |
| FY Dec 2021 | -140.7% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-14.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets HRTX
| FY Dec 2025 | -8.2% |
| FY Dec 2024 | -6.1% |
| FY Dec 2023 | -46.9% |
| FY Dec 2022 | -65.4% |
| FY Dec 2021 | -67.0% |
| Jun 2026 | -14.0% |
| Mar 2026 | -12.8% |
| Dec 2025 | -8.2% |
| Sep 2025 | -6.0% |
| Jun 2025 | -0.6% |
| Mar 2025 | -3.6% |
| Dec 2024 | -6.1% |
| Sep 2024 | -12.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital HRTX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-16.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed HRTX
| FY Dec 2025 | -1.7% |
| FY Dec 2024 | -8.1% |
| FY Dec 2023 | -71.0% |
| FY Dec 2022 | -86.6% |
| FY Dec 2021 | -89.7% |
| Jun 2026 | -16.3% |
| Mar 2026 | -6.9% |
| Dec 2025 | -1.7% |
| Sep 2025 | +1.1% |
| Jun 2025 | +2.2% |
| Mar 2025 | -2.5% |
| Dec 2024 | -8.1% |
| Sep 2024 | -18.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing HRTX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value HRTX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-21.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield HRTX
| FY Dec 2025 | -11.7% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -23.6% |
| FY Dec 2022 | -50.0% |
| FY Dec 2021 | -22.2% |
| Jun 2026 | -14.9% |
| Mar 2026 | -13.8% |
| Dec 2025 | -11.7% |
| Sep 2025 | -16.1% |
| Jun 2025 | -9.4% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing HRTX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $154.9M | $144.3M | $127.0M | $107.7M |
| Gross profit | $113.6M | $105.6M | $61.9M | $52.8M |
| Operating income | -$2.5M | -$11.5M | -$110.6M | -$174.7M |
| Net income | -$20.0M | -$14.0M | -$111.0M | -$182.0M |
| EPS (diluted) | -0.12 | -0.09 | -0.80 | -1.67 |
| Operating cash flow | -$27.6M | -$22.5M | -$58.8M | -$146.9M |
| Cash | $28.6M | $25.8M | $28.7M | $15.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
HRTX Stock Sonar score 4/7 axes
Find similar shapesCompareHRTX ranks highest on profitability (74th percentile) and growth (56th), and lowest on risk and compliance (24th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
